Keros Therapeutics Inc (KROS)
11.26 x 10 11.65 x 3
Post-market by (Cboe BZX)
11.44 +0.02 (+0.18%) 03/20/25 [NASDAQ]
11.26 x 10 11.65 x 3
Post-market 11.44 unch (unch) 16:01 ET
for Thu, Mar 20th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Sales | 3,550 | 151 | 0 | 20,100 | 0 |
Gross Profit | 3,550 | 151 | N/A | 20,100 | N/A |
Operating Expenses | 214,383 | 170,092 | 114,790 | 76,473 | 46,657 |
Operating Income | -210,833 | -169,941 | -114,790 | -56,373 | -46,657 |
Interest Expense | 0 | 0 | 1 | 4 | 6 |
Other Income | 23,780 | 16,949 | 10,112 | -356 | 1,130 |
Pre-tax Income | -187,053 | -152,992 | -104,679 | -56,733 | -45,533 |
Income Tax | 300 | N/A | N/A | 2,011 | -172 |
Net Income Continuous | -187,353 | -152,992 | -104,679 | -58,744 | -45,361 |
Net Income | $-187,353 | $-152,992 | $-104,679 | $-58,744 | $-45,361 |
EPS Basic Total Ops | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 |
EPS Basic Continuous Ops | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 |
EPS Diluted Total Ops | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 |
EPS Diluted Continuous Ops | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 |
EPS Diluted Before Non-Recurring Items | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 |
EBITDA(a) | $-209,604 | $-169,126 | $-114,116 | $-55,995 | $-46,379 |